Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Clinuvel Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2025 was 5.29.
Clinuvel Pharmaceuticals's debt to revenue ratio for the quarter that ended in Dec. 2025 was 0.00.
As of today, Clinuvel Pharmaceuticals's Altman Z-Score is 11.63.
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Clinuvel Pharmaceuticals has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Clinuvel Pharmaceuticals Financial Strength Related Terms
CLVLF vs VRTX, REGN, RVMD: Financial Strength Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Financial Strength vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Clinuvel Pharmaceuticals has a Z-score of 11.63, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 11.63 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (CLVLF) has a Financial Strength of 10 as of Dec. 2025. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Clinuvel Pharmaceuticals and its competitors. This is near median its historical median of 10.00. Over the past decade, Clinuvel Pharmaceuticals' Financial Strength has ranged from 9.00 to 10.00.
Is Clinuvel Pharmaceuticals' Financial Strength too high?
Clinuvel Pharmaceuticals' current Financial Strength of 10 is near median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 9.00 to a high of 10.00. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 92/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Financial Strength compare to VRTX and REGN?
Clinuvel Pharmaceuticals' Financial Strength of 10 can be compared against companies in the Biotechnology industry. Historically, Clinuvel Pharmaceuticals' own Financial Strength has ranged from 9.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Biotechnology company?
A good Financial Strength depends on the Biotechnology industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current Financial Strength is 10, which is near median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLF) is currently considered Significantly Undervalued. The stock's GF Value™ is $11.53, compared to a current price of $6.54 — trading 43.3% below its estimated fair value. The current Financial Strength is 10, which is near median its 10-year median of 10.00. Clinuvel Pharmaceuticals' overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLF), the current Financial Strength is 10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (CLVLF) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of $6.54 is trading 43.3% below its estimated GF Value™ of $11.53.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for CLVLF:
Financial Strength: 10 (near median its 10-year median of 10.00)
GF Value™: $11.53 vs. price of $6.54 (43.3% below fair value)
No single metric tells the full story. See the CLVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
92GF Score
Get the complete analysis for CLVLF
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVLF has been successfully added to your 
